menu
    • menu
    [{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"University of Georgia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"University of Georgia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"University of Arizona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ University of Arizona","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ University of Arizona"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"K1.1 mRNA","moa":"TFs and related regulators","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Jewish General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Biopharma \/ Jewish General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Jewish General Hospital"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"HEC88473","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sunshine Biopharma","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.93999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Biopharma \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"K1.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine Biopharma \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Nora Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pravastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunshine Biopharma \/ Sunshine Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Sunshine Biopharma

    Menu

    Sunshine Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches Doxycycline Therapy for STD, Acne, and Lyme Disease

                            Details : Doxycycline, an antibiotic, targets Matrix metalloproteinase 13, bacterial 70S ribosome, and other MMPs to treat respiratory tract infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 20, 2025

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pravastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Nora Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches Cholesterol-Fighting Pravastatin Medicine

                            Details : Pravastatin Sodium, a miscellaneous product targeting HMG-CoA reductase, shows promise in treating high cholesterol.

                            Product Name : Pravachol-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2025

                            Lead Product(s) : Pravastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Nora Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches Olanzapine and Olanzapine ODT

                            Details : Olanzapine is a 5-HT2A/2C/D2R inhibitor, indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders.

                            Product Name : Zyprexa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K1.1 mRNA

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Reports K1.1 mRNA Breakthrough for Liver Cancer Therapy

                            Details : K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology, it is currently being investigated as a novel therapeutic agent for human hepatocellular carcinoma.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : K1.1 mRNA

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches a New Generic Prescription Drug

                            Details : Ursodiol is indicated for the treatment of patients with Primary Biliary Cirrhosis. It inhibits the absorption of cholesterol and the secretion of cholesterol.

                            Product Name : Urso DS-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2024

                            Lead Product(s) : Ursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HEC88473

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Apollo Therapeutics

                            Deal Size : $938.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Apollo Licenses FGF21/GLP-1 Agonist from Sunshine Lake for Multi-Indications

                            Details : The agreement aims for the development of APL-18881 (HEC88473), a bi-specific fusion protein developed by Sunshine Lake that agonizes FGF21 and GLP-1 receptors in patients with type 2 diabetes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $12.0 million

                            November 12, 2024

                            Lead Product(s) : HEC88473

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Apollo Therapeutics

                            Deal Size : $938.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : University of Arizona

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treat...

                            Details : The License Agreement grants Sunshine Biopharma exclusive worldwide rights for all of the University of Arizona and University of Illinois Chicago technology pertaining to PLpro protease inhibitors of SARS-CoV-2, the coronavirus that causes COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : University of Arizona

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adva-27a

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Jewish General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adv...

                            Details : The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through IND-enabling studies. At any time the research results become conclusive, company will proceed to conducting a Phase I clinica...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 10, 2023

                            Lead Product(s) : Adva-27a

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Jewish General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K1.1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company...

                            Details : The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            November 16, 2022

                            Lead Product(s) : K1.1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Sunshine Biopharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective A...

                            Details : Recently communicated mRNA molecules GEM-difluorinated C-glycoside Derivative of Podophyllotoxin found in pre-clinical trials is effective at destroying cancer cells grown in culture.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 25, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth